Profitelligence Profitelligence · Filing Ledger Open DXCM research →

Form 8-K · Current Report · Filed 2026-01-12

Dexcom Reports Preliminary Q4 and FY 2025 Results, Provides FY 2026 Outlook

Dexcom, Inc. announced preliminary, unaudited financial results for the fourth quarter and full fiscal year 2025, reporting total revenue of approximately $1.260 billion for Q4 and $4.662 billion for FY 2025, with growth rates of 13% and 16% respectively. The company also provided an initial outlook for fiscal year 2026, anticipating total revenue between $5.16 - $5.25 billion, representing expected growth of approximately 11-13% over 2025. Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for 2026 was also provided.

Filer
Dexcom Inc. DXCM · NASDAQ
Filed
Accession
0001093557-26-000003
CIK
0001093557
Signal
Medium impactHealthcare

Items reported

Item events

Reported Item

Earnings Beat General Statement Financial Instrument Agreement

Market reaction

Close before filing

$67.40

Next session

+4.2%

Since filing

+23.8%

Latest close

$83.45

What happened, not what will happen — closing prices around the filing date.

About Dexcom Inc.

Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.

Exchange NASDAQ Industry Medical Devices Company website ↗

Never miss another DXCM filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts